![Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4eb8a236-ded3-4c80-b01b-23436bc85d78/gr1.jpg)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
![Geographies | Free Full-Text | Toward a Permafrost Vulnerability Index for Critical Infrastructure, Community Resilience and National Security Geographies | Free Full-Text | Toward a Permafrost Vulnerability Index for Critical Infrastructure, Community Resilience and National Security](https://www.mdpi.com/geographies/geographies-03-00027/article_deploy/html/images/geographies-03-00027-g001-550.jpg)
Geographies | Free Full-Text | Toward a Permafrost Vulnerability Index for Critical Infrastructure, Community Resilience and National Security
![Cancers | Free Full-Text | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises Cancers | Free Full-Text | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises](https://www.mdpi.com/cancers/cancers-14-00113/article_deploy/html/images/cancers-14-00113-g001.png)